Bradner W T, Schurig J E, Huftalen J B, Doyle G J
Cancer Chemother Pharmacol. 1980;4(2):95-101. doi: 10.1007/BF00254029.
This is an initial report on the development of screening tests for side effects of antitumor drugs, with small amounts of compound and short time intervals. These tests are based on acute dosing of mice and various blood or serum measurements: (a) total white blood cell count for leukopenia; (b) BUN for kidney toxicity; (c) SGPT for liver toxicity; and (d) creatine phosphokinase MB isozyme (CPK-MB) for cardiotoxicity. A correlation with the toxicity observed in other species is developed by establishing the effect of a prototype compound for each toxicity and tests of one or more compounds expected to lack such toxicity. On the basis of the limited number of compounds studied all four tests, although varying in sensitivity, seem to correlate with the results of tests in other species and with known effects in man. Final validation of these acute tests, especially the CPK-MB, will require both further study of histopathologic effects and correlation with results from clinical trials of an extended list of agents.
这是一份关于抗肿瘤药物副作用筛查试验开发的初步报告,试验使用的化合物量少且时间间隔短。这些试验基于对小鼠的急性给药以及各种血液或血清检测:(a) 白细胞减少症检测白细胞总数;(b) 肾毒性检测血尿素氮;(c) 肝毒性检测谷丙转氨酶;(d) 心脏毒性检测肌酸磷酸激酶MB同工酶(CPK-MB)。通过确定每种毒性的原型化合物的作用以及对一种或多种预期无此类毒性的化合物进行测试,建立与其他物种中观察到的毒性的相关性。基于所研究的化合物数量有限,所有这四项检测虽然灵敏度不同,但似乎都与其他物种的检测结果以及已知的人体效应相关。这些急性检测,尤其是CPK-MB检测的最终验证,将需要进一步研究组织病理学效应,并与更多药物的临床试验结果进行相关性分析。